In Alzheimer's disease (AD), CFH has been shown to be significantly downregulated (Lukiw et al., 2008; Hill et al., 2009; Pogue et al., 2009; Li et al., 2011, 2012; Lukiw, 2012) and might be a candidate plasma biomarker (Song et al., 2009). This evidence concerns the gene CFH and Alzheimer disease.